Your browser is no longer supported. Please, upgrade your browser.
ALIM Alimera Sciences, Inc. monthly Stock Chart
ALIM [NASD]
Alimera Sciences, Inc.
Index- P/E- EPS (ttm)-1.31 Insider Own1.50% Shs Outstand5.03M Perf Week-3.19%
Market Cap24.45M Forward P/E- EPS next Y-0.59 Insider Trans-6.22% Shs Float4.20M Perf Month-17.77%
Income-6.40M PEG- EPS next Q-0.44 Inst Own43.40% Short Float0.89% Perf Quarter-14.89%
Sales54.80M P/S0.45 EPS this Y-159.00% Inst Trans-2.37% Short Ratio0.80 Perf Half Y34.25%
Book/sh-7.53 P/B- EPS next Y48.70% ROA-13.10% Target Price- Perf Year-33.88%
Cash/sh2.68 P/C1.81 EPS next 5Y- ROE17.60% 52W Range- - 9.98 Perf YTD-35.88%
Dividend- P/FCF- EPS past 5Y-19.30% ROI-124.80% 52W High-51.30% Beta1.94
Dividend %- Quick Ratio3.00 Sales past 5Y45.00% Gross Margin86.70% 52W Low- ATR0.28
Employees122 Current Ratio3.20 Sales Q/Q-8.30% Oper. Margin-2.60% RSI (14)35.33 Volatility4.00% 4.38%
OptionableNo Debt/Eq- EPS Q/Q52.50% Profit Margin-11.70% Rel Volume0.50 Prev Close5.18
ShortableYes LT Debt/Eq- EarningsJul 29 AMC Payout- Avg Volume46.58K Price4.86
Recom2.00 SMA20-11.28% SMA50-18.10% SMA200-16.57% Volume23,112 Change-6.18%
May-28-19Initiated Craig Hallum Buy
Apr-27-17Initiated Rodman & Renshaw Buy $4
Nov-17-14Initiated Summer Street Research Buy $12
Sep-29-14Reiterated Northland Capital Outperform $7 → $10
Oct-28-13Upgrade Cowen Market Perform → Outperform
Oct-08-13Initiated Northland Capital Outperform $5
Nov-14-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Dec-27-10Reiterated Oppenheimer Outperform $16 → $14
Oct-11-10Initiated Rodman & Renshaw Mkt Outperform $13
Jun-02-10Initiated Oppenheimer Outperform $16
Sep-23-20 08:00AM  
Sep-15-20 08:00AM  
Sep-09-20 11:18AM  
08:00AM  
Sep-08-20 08:00AM  
Sep-01-20 10:10AM  
08:00AM  
Aug-31-20 05:00PM  
Aug-30-20 09:47AM  
Aug-26-20 08:30AM  
Aug-25-20 08:00AM  
Aug-13-20 08:00AM  
Aug-05-20 12:00PM  
11:44AM  
09:00AM  
Jul-31-20 12:30PM  
Jul-29-20 06:25PM  
05:32PM  
04:05PM  
Jul-23-20 11:15AM  
Jul-22-20 08:00AM  
Jul-09-20 08:00AM  
Jun-25-20 10:37AM  
Jun-23-20 06:36PM  
Jun-16-20 10:25AM  
Jun-10-20 06:04PM  
Jun-03-20 09:00AM  
08:00AM  
Apr-30-20 08:30PM  
Apr-29-20 06:25PM  
04:00PM  
Apr-24-20 08:00AM  
Apr-23-20 08:00AM  
Apr-13-20 08:36AM  
Mar-31-20 12:43PM  
08:00AM  
Mar-26-20 08:18AM  
Mar-25-20 08:00AM  
Feb-29-20 07:32AM  
Feb-26-20 06:35PM  
04:05PM  
Feb-24-20 08:00AM  
Feb-20-20 08:00AM  
Jan-29-20 04:52AM  
Jan-27-20 08:11AM  
Jan-10-20 04:11PM  
Jan-06-20 08:00AM  
Dec-17-19 07:20PM  
Dec-11-19 12:01PM  
Dec-04-19 08:30AM  
Dec-03-19 08:30AM  
Nov-26-19 08:30AM  
Nov-20-19 03:32AM  
Nov-14-19 12:45PM  
Nov-13-19 08:00AM  
Nov-08-19 08:14AM  
Nov-07-19 06:00PM  
Nov-05-19 08:30AM  
05:06AM  
Oct-29-19 04:42PM  
07:32AM  
Oct-25-19 08:30AM  
Oct-23-19 08:30AM  
Oct-03-19 08:30AM  
Oct-02-19 08:00AM  
Oct-01-19 08:00AM  
Sep-12-19 08:00AM  
Sep-05-19 08:00AM  
Sep-03-19 08:00AM  
Aug-06-19 07:24AM  
Aug-05-19 08:00AM  
Aug-03-19 09:25AM  
Jul-29-19 06:51PM  
Jul-23-19 08:00AM  
Jul-22-19 08:00AM  
Jul-19-19 08:00AM  
Jun-20-19 09:12AM  
08:00AM  
Jun-06-19 08:00AM  
Jun-04-19 05:34AM  
May-22-19 08:00AM  
May-21-19 08:24AM  
May-14-19 08:05AM  
May-05-19 11:04PM  
Apr-29-19 04:15PM  
Apr-23-19 04:30PM  
08:30AM  
Apr-04-19 08:00AM  
Mar-25-19 09:28AM  
Mar-21-19 08:00AM  
Mar-06-19 08:00AM  
Feb-20-19 03:43PM  
10:31AM  
Feb-19-19 07:00AM  
Feb-18-19 04:15PM  
Feb-05-19 07:30AM  
Feb-04-19 07:30AM  
Jan-30-19 11:07AM  
Jan-07-19 06:30AM  
Dec-21-18 11:36AM  
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myers C. DanielDirectorAug 20Sale6.735,00033,6505,578Aug 24 04:25 PM
Jones John PhilipChief Financial OfficerDec 10Buy9.291,0009,2949,536Dec 11 04:20 PM
Snisarenko JohnDirectorNov 21Buy4.9510,00049,50010,000Nov 25 04:17 PM
Largent James RDirectorNov 19Buy5.113,00015,3443,000Nov 20 05:19 PM